# Advancing Stillbirth Prevention Through Innovative Risk Evaluation (ASPIRE) Clinical Study

> **NCT07669935** · — · RECRUITING · sponsor: **Medicines360** · enrollment: 5500 (estimated)

## Conditions studied

- GDM
- Preterm Preeclampsia
- Preeclampsia
- Fetal Growth Restriction (FGR)
- Pregnancy Complications

## Interventions

- **OTHER:** None (this is an observational study with no intervention)

## Key facts

- **NCT ID:** NCT07669935
- **Lead sponsor:** Medicines360
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-08
- **Primary completion:** 2028-07-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 5500 (ESTIMATED)
- **Last updated:** 2026-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07669935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07669935, "Advancing Stillbirth Prevention Through Innovative Risk Evaluation (ASPIRE) Clinical Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07669935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*